Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on supporting clinical management of kidney disease. KidneyIntelX, Co.'s diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems, to generate a patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to support the allocation of treatments and clinical resources to patients at highest risk. The RNLX stock yearly return is shown above.
The yearly return on the RNLX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RNLX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|